Ostabolin inhalation - Nektar Therapeutics/Zelos Therapeutics
Alternative Names: Cyclic hPTH-(1-31)-NH2 inhalation; Ostabolin-C inhalation; Ostabolin-C inhalation powder; Ostabolin-C pulmonaryLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Nektar Therapeutics; Zelos Therapeutics Inc
- Class Osteoporosis therapies; Peptide fragments; Peptide hormones
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 21 Oct 2008 Novartis agrees to acquire certain areas of pulmonary business from Nektar
- 25 Sep 2007 Clinical data presented at the American Society for Bone and Mineral Research 29th Annual Meeting (ASBMR-2007) added to the adverse events, pharmacokinetics and Musculoskeletal Disorders pharmacodynamics sections ,
- 21 Sep 2006 Phase-I clinical trials in Osteoporosis in Canada (Inhalation)